Previous Close | 0.1150 |
Open | 0.1300 |
Bid | 0.1150 x N/A |
Ask | 0.1200 x N/A |
Day's Range | 0.1300 - 0.1300 |
52 Week Range | 0.0350 - 0.3050 |
Volume | |
Avg. Volume | 247,210 |
Market Cap | 25.256M |
Beta (5Y Monthly) | N/A |
PE Ratio (TTM) | N/A |
EPS (TTM) | -0.0800 |
Earnings Date | Nov 29, 2023 |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | N/A |
Second Bulk Sale for InsuJet(TM) Now Paid in Full Toronto, Ontario--(Newsfile Corp. - November 13, 2023) - NuGen Medical Devices Inc. (TSXV: NGMD) (the "Company" or "NuGen") is pleased to announce the Mexican government has completed the registration of NuGen's needle-free InsuJet™ injection device for sale throughout the country as a medical device.In May 2023, NuGen received its first bulk purchase order from Science-Link Trading SAPI de CV ("Science-Link"), a health and wellness company in ..
www.insujet.com - a diabetic e-commerce store Toronto, Ontario--(Newsfile Corp. - November 7, 2023) - NuGen Medical Devices Inc. (TSXV: NGMD) (the "Company" or "NuGen") a leading developer of needle-free devices to administer therapeutics subcutaneously, is pleased to announce the official launch on Shopify of its diabetic's lifestyle subscription business at www.insujet.com offering diabetics the ability to purchase our revolutionary needle-free InsuJet™ device and consumables online, direct to
Toronto, Ontario--(Newsfile Corp. - November 2, 2023) - NuGen Medical Devices Inc. (TSXV: NGMD) (the "Company" or "NuGen") a leading developer of needle-free devices to administer therapeutics subcutaneously, is pleased to report that Mr. Ian Heynen has commenced his role as the Company's new Chief Executive Officer focusing his attention on fully commercializing the Company with sales and manufacturing capabilities that drive growth while effectively managing the P&L. Bio of Mr. Ian Heynen:Mr.